Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The MONOVISC Hip Osteoarthritis Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02698865
Recruitment Status : Terminated (The results of the interim analysis indicate the futility criterion have been met, therefore enrollment was terminated.)
First Posted : March 4, 2016
Results First Posted : March 4, 2020
Last Update Posted : March 4, 2020
Sponsor:
Information provided by (Responsible Party):
DePuy Mitek

Brief Summary:
This study is being done to determine the effectiveness of MONOVISC for the relief of pain and symptoms of osteoarthritis of the hip. Specifically, the study will determine if MONOVISC is more effective than a placebo treatment when delivered as intra-articular injections (injected directly into the hip joint). In this case, the placebo will be a dilute solution of salt water (saline).

Condition or disease Intervention/treatment Phase
Osteoarthritis of the Hip Device: MONOVISC Device: Saline Phase 3

Detailed Description:
The primary objective of this study is determine whether two intra-articular injections of MONOVISC, separated by 1 month, are superior to two intra-articular injections of physiologic saline, separated by 1 month, in relieving hip osteoarthritis pain, as determined by reduction in walking pain change from baseline.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pivotal Study Comparing Two Injections of MONOVISC to Two Injections of Saline in Patients With Osteoarthritis of the Hip
Actual Study Start Date : January 1, 2016
Actual Primary Completion Date : March 15, 2019
Actual Study Completion Date : June 24, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MONOVISC
MONOVISC High Molecular Weight Hyaluronan
Device: MONOVISC
Two (2) intra-articular injections of 4 ml MONOVISC, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)

Placebo Comparator: Saline
Physiologic saline
Device: Saline
Two (2) intra-articular injections of 4 ml saline, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)




Primary Outcome Measures :
  1. Change From Baseline in Walking Pain as Measured by Western Ontario and McMaster Universities Arthritis Index (WOMAC) A1 Score at Day 180 [ Time Frame: Baseline and Day 180 ]
    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is widely used in the evaluation of Hip and Knee Osteoarthritis. Walking Pain Score is measured by question A1 on the WOMAC 3.1 Index. The WOMAC questionnaire used in this study was administered in the Numerical rating scale (NRS) format. Question A1 on the WOMAC 3.1 Index measures the amount of pain that a participant has when walking on a flat surface. It is one question that is collected on a scale from 0 to 10 where a score of 0 indicates no pain and a score of 10 indicates extreme pain.


Secondary Outcome Measures :
  1. Change From Baseline in Walking Pain as Measured by Western Ontario and McMaster Universities Arthritis Index (WOMAC) A1 Score at Day 14, 28, 60 and 120 [ Time Frame: Baseline, Day 14, 28, 60 and 120 ]
    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is widely used in the evaluation of Hip and Knee Osteoarthritis. Walking Pain Score is measured by question A1 on the WOMAC 3.1 Index. The WOMAC questionnaire used in this study was administered in the Numerical rating scale (NRS) format. Question A1 on the WOMAC 3.1 Index measures the amount of pain that a participant has when walking on a flat surface. It is one question that is collected on a scale from 0 to 10 where a score of 0 indicates no pain and a score of 10 indicates extreme pain.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female ≥ 30 years old
  • Body Mass Index (BMI) ≤ 35
  • Clinical or radiographic diagnosis of hip osteoarthritis in the target hip, with a Kellgren-Lawrence (K/L) grade of 2 or 3.
  • Walking pain NRS ≥ 4 and ≤ 8.
  • Willing to discontinue all pain medications (except rescue medication) for 7 days prior to the first study injection and for the duration of the study.
  • Willing to discontinue rescue medication for 48 hours prior to the first study injection.
  • Willing to discontinue rescue medication for 48 hours prior to all follow-up visits
  • Ability to tolerate acetaminophen (e.g. Tylenol).
  • Must be physically and mentally willing and able to comply with pre and post-treatment scheduled clinical and radiographic evaluations
  • Must voluntarily sign the Institutional Review Board approved Informed Consent Form.
  • Must agree not to initiate cannabis therapy during the trial study period.

Exclusion Criteria:

  • Radiographic evidence of osteonecrosis in the target hip
  • NRS walking pain ≥ 3 the contralateral hip
  • Clinically diagnosed osteoarthritis in either knee resulting in walking pain greater than NRS 5.
  • Dependence on external stabilization for walking (e.g. cane, crutches, walker, etc.)
  • Pain associated with lower back disorders that cannot be differentiated from target hip pain
  • Major dysplasia or congenital abnormality
  • Diagnosis of fibromyalgia
  • Primary inflammatory arthropathy, or any other condition affecting the joint, including rheumatoid arthritis or gout in the target hip
  • Any musculoskeletal condition that could impede efficacy measurement of the target hip
  • Any major surgery, arthroplasty, or arthroscopy of the lower extremities in the past 6 months, or planned surgery during the study
  • Infection of the injection site area
  • Chronic skin disorders that could interfere with injection site evaluation
  • Patients with asthma who require systemic use of corticosteroids
  • Septic arthritis in any joint in the past 12 weeks
  • For all patients: known hypersensitivity to hyaluronan, lidocaine, or acetaminophen
  • For patients undergoing fluoroscopic injection guidance: known hypersensitivity to iodine-based fluoroscopic contrast agents, shellfish, or iodine
  • Intra-articular steroid injection of the target hip within the last 3 months or hyaluronan injection of the target hip within the last 26 weeks
  • Systemic corticosteroids within the last 12 weeks
  • Glucosamine and/or chondroitin sulfate within last 4 weeks
  • Currently on anticoagulation therapy, including aspirin therapy of > 81 mg/day (e.g. one daily "baby aspirin").
  • Uncontrolled diabetes mellitus.
  • Pregnant or breast feeding, or plan to be pregnant during the course of the study
  • Any significant illness (metastasis of any type) that decreases the probability of the subject's survival to the 26 week endpoint
  • Patients unwilling/unable to complete a pain/function and quality of life questionnaires
  • Significant trauma to the index hip within 26 weeks of screening
  • Is receiving workman's compensation, or is currently involved in litigation relating to hip osteoarthritis
  • Is receiving prescription pain medication for conditions unrelated to hip osteoarthritis
  • Chronic use of narcotics
  • Unwilling to return for follow-up visits as described in this protocol
  • Otherwise determined by the investigator to be medically unsuitable for participation in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02698865


Locations
Show Show 27 study locations
Sponsors and Collaborators
DePuy Mitek
Investigators
Layout table for investigator information
Study Director: Brooks J Story, PhD DePuy Synthes Mitek Sports Medicine
  Study Documents (Full-Text)

Documents provided by DePuy Mitek:
Study Protocol  [PDF] October 30, 2017
Statistical Analysis Plan  [PDF] March 1, 2016

Layout table for additonal information
Responsible Party: DePuy Mitek
ClinicalTrials.gov Identifier: NCT02698865    
Other Study ID Numbers: 15-MVH-01
First Posted: March 4, 2016    Key Record Dates
Results First Posted: March 4, 2020
Last Update Posted: March 4, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Hip
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents